<DOC>
	<DOCNO>NCT00652626</DOCNO>
	<brief_summary>The purpose study evaluate three thing . The first whether azacitidine absorb body rate proportion different concentration . The second determine effect renal impairment absorption azacitidine . The third determine azacitidine safe well tolerated patient renal function impairment .</brief_summary>
	<brief_title>Pharmacokinetics Safety Study Azacitidine Cancer Patients With Without Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis one following : MDS accord FrenchAmericanBritish ( FAB ) classification system : refractory anemia ( RA ) , refractory anemia ring sideroblast ( RARS ) , refractory anemia excess blast ( RAEB ) , refractory anemia excess blast transformation ( RAEBT ) , chronic myelomonocytic leukemia ( CMML ) ; Acute myelogenous leukemia ( AML ) remission , Malignant solid tumor , Multiple myeloma ( MM ) , NonHodgkin lymphoma ( NHL ) , Hodgkin lymphoma ( HD ) Patients history treat brain metastasis clinically stable great 4 week prior sign inform consent form glucocorticoid therapy central nervous system ( CNS ) edema least 4 week Be capable give informed consent Have Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Have life expectancy ≥ 3 month Have stable renal function least 2 month Have average calculate creatinine clearance : &gt; 80 mL/min/1.73m^2 Cohorts 1 , 2 , 3 , 4 &lt; 30 mL/min/1.73m^2 Cohort 5 Severe renal impairment , 5080 mL/min/1.73m^2 Cohort 6 Mild renal impairment , 30 &lt; 50 mL/min/1.73m^2 Cohort 7 Moderate renal impairment Have organ marrow function screen predose visit define : Hemoglobin ≥8 g/dL , Absolute neutrophil count ≥0.75 x 10^3/µL , Platelets ≥30 x 10^3/µL , Total bilirubin ≤1.5 time upper limit normal ( ULN ) , Aspartate aminotransferase ( AST ) ≤2 time ULN , Alanine transaminase ( ALT ) ≤2 time ULN ; Have 12lead electrocardiogram ( ECG ) clinically significant , determined Investigator , screen Have serum bicarbonate : 20 mEq/L patient normal renal function ( cohorts 1 , 2 , 3 4 ) , 16 mEq/L patient impaired renal function ( cohorts 5 , 6 7 ) Women childbearing potential may participate , provide pregnant agree use least 2 effective contraceptive method throughout study Males female partner childbearing potential must agree use least 2 effective contraceptive method throughout study avoid father child 6 month follow date last dose study medication Be nonsmoker must smoke least 30 day screen visit agree abstain smoking study participation Women pregnant nursing ; Had chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior sign inform consent Have treat investigational agent within 4 week prior sign inform consent form Have ongoing clinically significant adverse event ( ) due chemotherapy , radiotherapy investigational agent administer 4 week prior sign inform consent determine Investigator Have know suspected hypersensitivity azacitidine mannitol Have uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia Have low blood pressure ( supine blood pressure &lt; 90/60 mmHg ) Have human immunodeficiency virus ( HIV ) , active hepatitis virus B C Have advance malignant hepatic tumor Have end stage renal disease require dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>MDS</keyword>
	<keyword>AML</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>PK</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Renal Impairment</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Hodgkin 's Disease</keyword>
</DOC>